Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

- Significant clinical progress noted in small cell lung, prostate and

colorectal cancer trials -

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today provided an update of its picoplatin development program in small cell lung cancer (SCLC), colorectal cancer (CRC) and hormone refractory prostate cancer (HRPC), and its oral formulation in solid tumors. Presenting at the Lazard Capital Markets Healthcare Conference in New York, Jerry McMahon, Ph.D., chairman and CEO of Poniard, noted that the Company has made significant progress in 2007 in its clinical development program for picoplatin, its lead product candidate.

"2007 has been an important year for Poniard, as we have continued to advance our development of picoplatin, a new generation chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations," said Dr. McMahon. "We continue to drive our clinical programs toward completion and have achieved significant milestones this year. In addition, we remain on track to file our NDA for picoplatin in 2009."

Poniard is providing an update on the progress on all four of its picoplatin clinical trials, as follows:

Phase 3 SPEAR Trial:

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

To date
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ( ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram Devices ... 2016. The North America accounts ... while Europe claims approximately 27% ...
(Date:12/15/2014)... Research and Markets , ... has announced the addition of the "Cardiac Guidewires ... their offering. Global Guidewires sector is projected to ... America accounts for nearly 35% (2015) of ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... YORK and HERZLIYA PITUACH, Israel ... "Company") (NASDAQ: IMNP ) announced today that its ... the Board succeeding Dr. Daniel Teper who continues ... a member of Immune,s Board of Directors since 2013. ... "I am delighted to represent the interest of shareholders and ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2012 Seventeen Banner Health facilities have achieved Stage ... medical record (EMR) as acknowledged by HIMSS Analytics, a ... Management Systems Society. HIMSS Analytics monitors and recognizes levels ... the United States, Canada and other countries. ...
... (NYSE: WPI ), a leading specialty global pharmaceutical ... Executive Officer, will provide an overview and update of the ... Healthcare Conference on Wednesday, May 16, 2012 at 10:00 AM ... Vegas, Nevada. The presentation will be webcast live and can ...
Cached Medicine Technology:Seventeen Banner Health facilities achieve final stage of electronic medical record adoption 2Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference 2
(Date:12/17/2014)... HeartMath® Inc., recognized as one of ... variability (HRV), heart coherence and the physiology of ... and algorithms to chipset manufacturers and consumer electronics ... to offer its HRV solutions, tap into its ... its normative HRV databases and algorithms for developing ...
(Date:12/17/2014)... December 17, 2014 Project Veritas is ... brought videos of MIT economist and Obamacare architect Jonathan ... James O’Keefe conducted the interview, which is being distributed ... there was intentional mislabeling in the Affordable Care Act ... bill: A two-hundred-and-fifty billion dollar per year tax grab. ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Greater participation ... new study finds. Researchers followed kids in the ... to poor children in Los Angeles. Over two ... larger improvements in how the brain processes speech and ... Also, the benefits of active participation in music ...
(Date:12/15/2014)... December 15, 2014 Cancer researchers have ... underlying genetic causes of deadly malignant pleural mesothelioma. Surviving ... on their website. Click here to read it ... of Hawaii Cancer Center, and New York’s Langone Medical ... pleural mesothelioma patients in an effort to pinpoint ...
(Date:12/15/2014)... OutMarket , a provider of marketing ... Cheat Sheets ,” a guide that exposes the insider ... the top ten social media networks. , Social ... engagement, and customer service. It can also increase new ... on new networks and weather constantly changing algorithms, they ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3
... factor in poor sleep, a new survey of more than 150,000 ... a lifetime, with the fewest complaints coming from people in their ... Michael Grandner, PhD, lead author of the study. "These results force ... men and women." The study, appearing in the March ...
... HOUSTON - A drug that relieves the severe symptoms of ... survival of patients with the disease, according to a phase ... New England Journal of Medicine . "The Phase ... for many patients with myelofibrosis and now this phase III ...
... News) -- Strict enforcement of underage drinking laws reduces the ... a new study suggests. State lawmakers have relied heavily ... possession of alcohol under the legal age laws -- to ... information on young people aged 15 to 24 from the ...
... HealthDay Reporter , WEDNESDAY, Feb. 29 (HealthDay News) ... flu and Parkinson,s disease appears to speed recovery in ... Traumatic brain injury (TBI) victims who weren,t fully conscious ... given amantadine hydrochloride. The drug is already given "off-label" ...
... Queen,s obstetrics professor has founded one of the first clinics ... a key opportunity in a woman,s life to focus on ... else is doing this at present," says Graeme Smith, who ... , Pregnancy is a stress test in that it can ...
... 2012)Bacteria live in a state of perpetual warfare, with ... when pathogen, over their infected host. New research suggests ... disease cholera, kills off its microbial rivals by jabbing ... for that defense, called the Type 6 secretion system ...
Cached Medicine News:Health News:Study: Sleep gets better with age, not worse 2Health News:Drug improves survival and quality of life for people with myelofibrosis 2Health News:Drug improves survival and quality of life for people with myelofibrosis 3Health News:Strict Underage Drinking Laws May Deter Delinquency in Teens 2Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 2Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 3Health News:Drug Seems to Speed Recovery After Traumatic Brain Injury 4Health News:Cholera's nano-dagger 2Health News:Cholera's nano-dagger 3
... RSV antigen test is a ... the presumptive qualitative detection of ... nasopharyngeal specimens in neonatal and ... minute test has a built-in ...
One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Medicine Products: